Is recombinant human erythropoietin (rh-epo) more than just a treatment of anemia in cancer and chemotherapy?
作者信息
Taylor S K
机构信息
Department of Anaesthesiology, University of Heidelberg, Heidelberg, Germany. sakitaylor@ aol.com
出版信息
Med Hypotheses. 2003 Jan;60(1):89-93. doi: 10.1016/s0306-9877(02)00337-7.
Abstract
Recombinant human eythropoietin (rh-epo) is a well established treatment for many kinds of anemia including the anemia of cancer with or without myelosuppressive chemotherapy. This review considers the effects of rh-epo in humans, tumour-bearing and healthy experimental animals treated with cisplatin with or without rh-epo, and proposes that the ability of rh-epo to improve the quality of life in cancer patients may also be due to interference with the prostaglandin pathways.
摘要
Zotero 插件